Cellular & Genetic
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Something fundamental has shifted in cell therapy investment over the past 18 months. No longer about which science works, it has evolved around the question of which business model pharma believes it can scale. Increasingly, that question is being answered before a single patient is enrolled.
Pioneering immunologist, Prof. Bruce Levine from UPenn, wears his passion for CAR-T cell therapy on his sleeve as he highlights future uses of the therapy, predictive markers and off-the-shelf CAR-T while speaking about a journey from Kymriah co-inventor to country music co-writer
Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.
The company said the NEAT trial in ataxia telangiectasia did not meet the primary and key secondary endpoints.
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
Investors and analysts say cell and gene therapy is entering a disciplined “phoenix” phase, with selective risk taking, AI enabled platforms and new pricing models redefining how one time cures attract capital.
Cellafa Bioscience, an Astellas-Yaskawa joint venture, uses Maholo robotic automation and AI to standardize cell therapy manufacturing, targeting GMP compliance within two years and global expansion.
In an exclusive interview, Generics Bulletin spoke to a trio of experts who argue that biosimilar cell and gene therapies are technically within reach but demand unprecedented regulatory clarity, manufacturing evolution and economic alignment before they become reality.